Explore Stanford technologies available for licensing:

While conventionally known for its function as an inhibitory neurotransmitter, GABA signaling was recently discovered to have a significant role in fate determination of blood stem cells.

Stanford researchers have developed multivalent SIRP-alpha fusion polypeptides that selectively block the CD47–SIRP-alpha immune checkpoint with enhanced potency, enabling next-generation immunotherapies that promote immune clearance of cancer and diseased cells while minimizi

Stanford researchers have developed a more sensitive and accurate pathogenic infection diagnosis method using intact genetically modified pathogens. Pathogen infection clinical diagnosis requires direct pathogen detection or the detection of pathogen specific antibodies.

Researchers at Stanford have discovered a therapeutic strategy to overcome off-target red blood cell (RBC) toxicity associated with anti-CD47 antibody cancer therapies and possibly antibody-mediated autoimmune anemia and thrombocytopenia.

Stanford inventors have developed a method to efficiently differentiate human pluripotent stem cells (hPSCs) into nearly pure populations of human blood progenitors or blood vessel cells in a Petri dish.

Researchers at Stanford University have developed a novel therapeutic avenue for the treatment of osteoporosis and other musculoskeletal diseases.

Researchers at Stanford have developed a novel method for the isolation of neural stem and progenitor cells (NSPCs).

Stanford researchers have found that a chemokine receptor antagonist can reduce immunosuppression in the tumor microenvironment and thereby delay tumor progression.

Obtaining pure cell types from mixed cell populations continues to be a significant obstacle in the fields of stem cell biology and regenerative medicine.

Coronary artery disease is the leading cause of death worldwide, yet coronary artery development and regeneration remain poorly understood.

Stanford researchers have found that aging and disease lead to skeletal stem cell (SSC) dysfunction and hence decreased bone health.

Researchers in Prof. Irving Weissman's laboratory have produced a mouse to identify and isolate mouse long-term hematopoietic stem cells.

Researchers at Stanford have developed agents to enhance the therapeutic efficacy of a variety of anti-cancer therapeutics. Cell loss by apoptosis occurs in normal development and in tumor environments.

Please see issued patent and publication, below, for details.

Researchers in Prof. Irving Weissman's laboratory have developed cell culture techniques to rapidly and efficiently derive pure populations of mesodermal cells from human pluripotent stem cells (hPSCs).